What would be an appropriate chemotherapy de-escalation strategy for patients with metastatic TNBC on pembrolizumab/chemotherapy with CR and negative ctDNA?

My inclination would be to stop the chemotherapy but continue pembrolizumab indefinitely, in the absence of an immune-related adverse event (that can't be easily controlled, such as hypothyroidism).